Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Aligos Therapeutics, Inc. | Director | Common Stock | 11M | $8.34M | $0.76 | Oct 25, 2023 | Indirect |
Aligos Therapeutics, Inc. | Director | Warrant (Right to Buy) | 3.97M | Oct 25, 2023 | Indirect | ||
Aligos Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 60K | Jun 27, 2024 | Direct | ||
Entrada Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 11.9K | Jun 2, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ALGS | Aligos Therapeutics, Inc. | Jun 27, 2024 | 1 | $0 | 4 | Jun 28, 2024 | Director |
ALGS | Aligos Therapeutics, Inc. | Feb 27, 2024 | 2 | $0 | 4 | Feb 28, 2024 | Director |
ALGS | Aligos Therapeutics, Inc. | Oct 25, 2023 | 2 | $6.5M | 4 | Oct 27, 2023 | Director, 10%+ Owner |
ALGS | Aligos Therapeutics, Inc. | Jul 20, 2023 | 1 | $0 | 4 | Jul 21, 2023 | Director |
ALGS | Aligos Therapeutics, Inc. | Jun 23, 2022 | 1 | $0 | 4 | Jun 27, 2022 | Director |
TRDA | Entrada Therapeutics, Inc. | Jun 2, 2022 | 1 | $0 | 4 | Jun 6, 2022 | Director |
TRDA | Entrada Therapeutics, Inc. | Oct 28, 2021 | 1 | $0 | 4 | Nov 1, 2021 | Director |
TRDA | Entrada Therapeutics, Inc. | Oct 28, 2021 | 0 | $0 | 3 | Oct 28, 2021 | Director |
ALGS | Aligos Therapeutics, Inc. | Jun 17, 2021 | 1 | $0 | 4 | Jun 17, 2021 | Director |